Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2016
PHARMAC decision relating to filgrastim and methotrexate pre-filled syringes
5 February 2016 - PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Ltd. involving filgrastim, ...
Posted by Michael Wonder on 03 Feb 2016
Request for proposals - influenza vaccine
3 February 2016 - PHARMAC invites proposals for the supply of seasonal influenza vaccine in New Zealand. ...
Posted by Michael Wonder on 03 Feb 2016
PHARMAC decision to widen access to budesonide with eformoterol (Symbicort Turbuhaler and Vannair)
3 February 2016 - From 1 March 2016, the effect of the decision is that: ...
Posted by Michael Wonder on 03 Feb 2016
PHARMAC decision relating to a number of respiratory products
3 February 2016 - PHARMAC is pleased to announce the approval of agreements with Boehringer Ingleheim and GlaxoSmithKline involving a number ...
Posted by Michael Wonder on 01 Feb 2016
Dad pushing for a subsidy on EpiPens
30 January 2016 - A Whanganui father wants EpiPens to be funded by PHARMAC. ...
Posted by Michael Wonder on 31 Jan 2016
New Zealand Pharmaceutical Schedule - 1 February 2016 update
1 February 2016 - The second issue of the Schedule for 2016 sees the listing of two new medicines: dimethyl ...
Posted by Michael Wonder on 31 Dec 2015
New Zealand Pharmaceutical Schedule - 1 January 2016 update
31 December 2015 - The first issue of the New Zealand Pharmaceutical Schedule for 2016 sees the listing of a ...
Posted by Michael Wonder on 20 Dec 2015
Filgrastim and methotrexate prefilled syringe proposal with Novartis New Zealand Ltd
21 December 2015 - PHARMAC is seeking feedback on a proposal involving filgrastim and methotrexate prefilled syringes, resulting from a provisional ...
Posted by Michael Wonder on 14 Dec 2015
Budesonide with eformoterol (Symbicort Turbuhaler and Vannair) proposal with Astra Zeneca
15 December 2015 - PHARMAC is seeking feedback on a proposal involving budesonide with eformoterol inhalers (Symbicort Turbuhaler and Vannair), which ...
Posted by Michael Wonder on 13 Dec 2015
Mesalazine (Asacol) 800 mg tablets approved in NZ
11 December 2015 - PHARMAC is pleased to announce the approval of an agreement with Baxter Healthcare Limited to fund Asacol ...
Posted by Michael Wonder on 09 Dec 2015
New treatment options for patients with multiple sclerosis
9 December 2015 - Funding for two new medicines will provide patients with more convenient options for treating multiple sclerosis. ...
Posted by Michael Wonder on 05 Dec 2015
PHARMAC decisions relating to new multiple sclerosis treatments
4 December 2015 - PHARMAC is pleased to announce the approval of proposals to fund two new treatments for Multiple Sclerosis ...
Posted by Michael Wonder on 04 Dec 2015
PHARMAC decision puts cancer patients at risk - Cancer Society
3 December 2015 - This is the fourth time funding has been declined for a melanoma treatment by Pharmac. ...
Posted by Michael Wonder on 03 Dec 2015
Melanoma drug given low funding priority
2 December 2015 - The new drug, Keytruda, hailed as a historic step forward in the treatment of advanced melanoma, has ...
Posted by Michael Wonder on 02 Dec 2015
Decision to retain first-line biologic access for adalimumab in dermatology and rheumatology indications
2 December 2015 - PHARMAC is pleased to announce the approval of an agreement with AbbVie Limited to reduce the price ...